What patents cover riociguat (Adempas) and what are they for?
Riociguat (brand name Adempas for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension) is protected by multiple patent families rather than a single patent. Different patents typically cover specific parts of the invention, such as the drug substance, specific chemical forms or polymorphs, manufacturing/process methods, and particular therapeutic uses or dosage regimens.
Because patent coverage is jurisdiction-specific (US vs. EU vs. UK vs. other countries), the exact list of active patents and their remaining life depends on where you are looking and on whether you mean “base compound patents” or later-filed “follow-on” patents. The material available in the prompt does not include a patent register or specific patent numbers, so I can’t name the exact riociguat patents from your request alone.
When do riociguat patents expire (and why the date can differ by country)?
Riociguat patent expiry varies by country due to:
- Different filing dates and legal deadlines for the underlying patent families.
- Country-by-country rules on patent term adjustments.
- Separate protections for different aspects (e.g., drug substance vs. use vs. formulation).
- Possible regulatory exclusivities and supplementary protection mechanisms (where available), which can extend market exclusivity even if some patents expire earlier.
To determine the real “end date” for competitors or for generic/biosimilar market entry, you usually need the latest status for each jurisdiction and each relevant patent family, not just the earliest compound patent.
Are there follow-on patents that extend riociguat protection?
Yes, it is common for drugs like riociguat to have follow-on patents after the original compound filing. These can include patents on:
- Specific salts/solid forms or crystallinity.
- Tablet/capsule formulations and manufacturing processes.
- Additional indications or dosing schedules.
Those patents can delay generic entry even when earlier compound patents expire, depending on what claims are enforced and on whether a generic product can be designed around them.
How do you check whether a specific riociguat patent is still in force?
The practical way is to search by:
- Jurisdiction patent databases (e.g., USPTO for US; EPO and national registers for Europe).
- Brand-name linked reference sources (for example, “Adempas” in patent landscape searches).
- Patent status tools that show whether a patent is granted, expired, lapsed, or under legal challenge.
If you tell me the country (US, EU, UK, etc.) and whether you care about compound patents, formulation/process patents, or use patents, I can outline the most direct search route and the fields to check (publication number, priority date, grant date, legal status, and any maintenance fee lapses).
Can generic or other competitors launch before all riociguat patents expire?
Sometimes. Market entry can happen if:
- A competitor’s product does not infringe the remaining enforceable claims (design-around).
- Certain patents are not asserted, are invalidated, or are no longer in force.
- Legal frameworks allow entry “at risk” while patent litigation is pending.
However, the exact outcome depends on the patent-by-patent infringement landscape and the legal status in the relevant jurisdiction.
What info do you need from me to identify the exact riociguat patents?
To give you a precise list (with expiry dates) I need at least:
1) Which jurisdiction(s): US, EU countries, UK, Canada, etc.
2) Whether you want “all relevant patents” or only the ones that control exclusivity/entry.
3) If you have a particular patent number, publication, or assignee name you’ve seen (e.g., Bayer or related entities), share that so I can map the family.
Reply with the country/region you care about and I’ll narrow to the specific riociguat patent families and their likely expiry windows.